110 related articles for article (PubMed ID: 8147091)
21. A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge.
Calvo-Calle JM; Oliveira GA; Watta CO; Soverow J; Parra-Lopez C; Nardin EH
Infect Immun; 2006 Dec; 74(12):6929-39. PubMed ID: 17030584
[TBL] [Abstract][Full Text] [Related]
22. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
Bojang KA; Milligan PJ; Pinder M; Vigneron L; Alloueche A; Kester KE; Ballou WR; Conway DJ; Reece WH; Gothard P; Yamuah L; Delchambre M; Voss G; Greenwood BM; Hill A; McAdam KP; Tornieporth N; Cohen JD; Doherty T;
Lancet; 2001 Dec; 358(9297):1927-34. PubMed ID: 11747915
[TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
Abdulla S; Oberholzer R; Juma O; Kubhoja S; Machera F; Membi C; Omari S; Urassa A; Mshinda H; Jumanne A; Salim N; Shomari M; Aebi T; Schellenberg DM; Carter T; Villafana T; Demoitié MA; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
N Engl J Med; 2008 Dec; 359(24):2533-44. PubMed ID: 19064623
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.
Genton B; Al-Yaman F; Anders R; Saul A; Brown G; Pye D; Irving DO; Briggs WR; Mai A; Ginny M; Adiguma T; Rare L; Giddy A; Reber-Liske R; Stuerchler D; Alpers MP
Vaccine; 2000 May; 18(23):2504-11. PubMed ID: 10775784
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
27. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.
Stewart VA; McGrath SM; Dubois PM; Pau MG; Mettens P; Shott J; Cobb M; Burge JR; Larson D; Ware LA; Demoitie MA; Weverling GJ; Bayat B; Custers JH; Dubois MC; Cohen J; Goudsmit J; Heppner DG
Infect Immun; 2007 May; 75(5):2283-90. PubMed ID: 17307942
[TBL] [Abstract][Full Text] [Related]
28. A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines.
Kostense S; Mommaas B; Hendriks J; Verhoeven M; Ter Haak M; Tirion F; Wiesken E; Pau MG; Radosevic K; Goudsmit J
Clin Vaccine Immunol; 2011 May; 18(5):776-82. PubMed ID: 21411600
[TBL] [Abstract][Full Text] [Related]
29. SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand.
Migasena S; Heppner DG; Kyle DE; Chongsuphajaisiddhi T; Gordon DM; Suntharasamai P; Permpanich B; Brockman A; Pitiuttutham P; Wongsrichanalai C; Srisuriya P; Phonrat B; Pavanand K; Viravan C; Ballou WR
Acta Trop; 1997 Sep; 67(3):215-27. PubMed ID: 9241386
[TBL] [Abstract][Full Text] [Related]
30. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of
Jongo SA; Shekalaghe SA; Church LWP; Ruben AJ; Schindler T; Zenklusen I; Rutishauser T; Rothen J; Tumbo A; Mkindi C; Mpina M; Mtoro AT; Ishizuka AS; Kassim KR; Milando FA; Qassim M; Juma OA; Mwakasungula S; Simon B; James ER; Abebe Y; Kc N; Chakravarty S; Saverino E; Bakari BM; Billingsley PF; Seder RA; Daubenberger C; Sim BKL; Richie TL; Tanner M; Abdulla S; Hoffman SL
Am J Trop Med Hyg; 2018 Aug; 99(2):338-349. PubMed ID: 29943719
[TBL] [Abstract][Full Text] [Related]
31. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children.
Genton B; Al-Yaman F; Betuela I; Anders RF; Saul A; Baea K; Mellombo M; Taraika J; Brown GV; Pye D; Irving DO; Felger I; Beck HP; Smith TA; Alpers MP
Vaccine; 2003 Dec; 22(1):30-41. PubMed ID: 14604568
[TBL] [Abstract][Full Text] [Related]
33. The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.
Audran R; Lurati-Ruiz F; Genton B; Blythman HE; Ofori-Anyinam O; Reymond C; Corradin G; Spertini F
PLoS One; 2009 Oct; 4(10):e7304. PubMed ID: 19798415
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
35. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.
Ouédraogo A; Tiono AB; Kargougou D; Yaro JB; Ouédraogo E; Kaboré Y; Kangoye D; Bougouma EC; Gansane A; Henri N; Diarra A; Sanon S; Soulama I; Konate AT; Watson NL; Brown V; Hendriks J; Pau MG; Versteege I; Wiesken E; Sadoff J; Nebie I; Sirima SB
PLoS One; 2013; 8(11):e78679. PubMed ID: 24244339
[TBL] [Abstract][Full Text] [Related]
36. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.
Rampling T; Ewer KJ; Bowyer G; Bliss CM; Edwards NJ; Wright D; Payne RO; Venkatraman N; de Barra E; Snudden CM; Poulton ID; de Graaf H; Sukhtankar P; Roberts R; Ivinson K; Weltzin R; Rajkumar BY; Wille-Reece U; Lee CK; Ockenhouse CF; Sinden RE; Gerry S; Lawrie AM; Vekemans J; Morelle D; Lievens M; Ballou RW; Cooke GS; Faust SN; Gilbert S; Hill AV
J Infect Dis; 2016 Sep; 214(5):772-81. PubMed ID: 27307573
[TBL] [Abstract][Full Text] [Related]
37. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
[TBL] [Abstract][Full Text] [Related]
38. Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia.
Bojang K; Milligan P; Pinder M; Doherty T; Leach A; Ofori-Anyinam O; Lievens M; Kester K; Schaecher K; Ballou WR; Cohen J
Hum Vaccin; 2009 Apr; 5(4):242-7. PubMed ID: 19276646
[TBL] [Abstract][Full Text] [Related]
39. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.
Aide P; Dobaño C; Sacarlal J; Aponte JJ; Mandomando I; Guinovart C; Bassat Q; Renom M; Puyol L; Macete E; Herreros E; Leach A; Dubois MC; Demoitie MA; Lievens M; Vekemans J; Loucq C; Ballou WR; Cohen J; Alonso PL
Vaccine; 2011 Aug; 29(35):6059-67. PubMed ID: 21443960
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
Kester KE; McKinney DA; Tornieporth N; Ockenhouse CF; Heppner DG; Hall T; Krzych U; Delchambre M; Voss G; Dowler MG; Palensky J; Wittes J; Cohen J; Ballou WR;
J Infect Dis; 2001 Feb; 183(4):640-7. PubMed ID: 11170991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]